Drug Search Results
More Filters [+]

OCV-C02

Alternative Names: ocv-c02, ocv c02, ocvc02, ocv-103, ocv103, ocv 103, ocv-104, ocv104, ocv 104
Latest Update: 2021-01-12
Latest Update Note: Clinical Trial Update

Product Description

OCV-C02 is a peptide vaccine consisting of two peptide epitopes derived from ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34 (TOMM34). a peptide vaccine consisting of two peptide epitopes for refractory metastatic colorectal cancer (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28266765/)

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Otsuka
Company Location: NEW YORK NY 10271
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for OCV-C02

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Colorectal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

JapicCTI-132075

P1

Completed

Colorectal Cancer

2015-01-01

JapicCTI-132075

P1

Unknown

Colorectal Cancer

2015-01-01

Recent News Events

Date

Type

Title